Home » Stocks » PHAR

Pharming Group N.V. (PHAR)

Stock Price: $11.54 USD 0.12 (1.05%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 738.56M
Revenue (ttm) 226.46M
Net Income (ttm) 40.29M
Shares Out 64.00M
EPS (ttm) 0.59
PE Ratio 19.71
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $11.54
Previous Close $11.42
Change ($) 0.12
Change (%) 1.05%
Day's Open -
Day's Range 11.37 - 11.54
Day's Volume 106
52-Week Range 10.80 - 21.99

News

Hide News

Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") under the s...

7 months ago - PR Newswire

Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical...

8 months ago - PR Newswire UK

Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC

About PHAR

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated ... [Read more...]

Industry
Research and Development in Biotechnology
Founded
1988
CEO
Sijmen de Vries
Employees
262
Stock Exchange
NASDAQ
Ticker Symbol
PHAR
Full Company Profile

Financial Performance

In 2020, Pharming Group's revenue was 185.69 million, an increase of 9.86% compared to the previous year's 169.02 million. Earnings were 33.04 million, a decrease of -8.73%.

Financial numbers in millions EUR.
Financial Statements